Cellectis S.A. (CLLS)
NASDAQ: CLLS · Real-Time Price · USD
3.090
-0.290 (-8.58%)
At close: Jun 3, 2026, 4:00 PM EDT
3.110
+0.020 (0.64%)
After-hours: Jun 3, 2026, 7:14 PM EDT
Cellectis Revenue
Cellectis had revenue of $7.55M in the quarter ending March 31, 2026, a decrease of -37.25%. This brings the company's revenue in the last twelve months to $75.11M, up 37.20% year-over-year. In the year 2025, Cellectis had annual revenue of $79.59M with 61.72% growth.
Revenue (ttm)
$75.11M
Revenue Growth
+37.20%
P/S Ratio
3.03
Revenue / Employee
$328,000
Employees
229
Market Cap
227.37M
Revenue Chart
Revenue History
| Fiscal Year End | Revenue | Change | Growth |
|---|---|---|---|
| Dec 31, 2025 | 79.59M | 30.38M | 61.72% |
| Dec 31, 2024 | 49.22M | 40.02M | 435.37% |
| Dec 31, 2023 | 9.19M | -16.53M | -64.26% |
| Dec 31, 2022 | 25.72M | -12.87M | -33.35% |
| Dec 31, 2021 | 38.60M | -20.97M | -35.20% |
| Dec 31, 2020 | 59.56M | 36.57M | 159.09% |
| Dec 31, 2019 | 22.99M | 1.56M | 7.27% |
| Dec 31, 2018 | 21.43M | -12.28M | -36.43% |
| Dec 31, 2017 | 33.72M | -22.73M | -40.27% |
| Dec 31, 2016 | 56.45M | -6.12M | -9.78% |
| Dec 31, 2015 | 62.57M | 30.56M | 95.47% |
| Dec 31, 2014 | 32.01M | 14.51M | 82.92% |
| Dec 31, 2013 | 17.50M | -10.25M | -36.93% |
| Dec 31, 2012 | 27.74M | 7.04M | 34.00% |
| Dec 31, 2011 | 20.70M | -248.60K | -1.19% |
| Dec 31, 2010 | 20.95M | 6.11M | 41.19% |
| Dec 31, 2009 | 14.84M | -2.65M | -15.16% |
| Dec 31, 2008 | 17.49M | - | - |
Revenue Definition
Revenue, also called sales, is the amount of money a company receives from its business activities, such as sales of products or services. Revenue does not take any expenses into account and is therefore different from profits.
Full DefinitionRelated Stocks
| Company Name | Revenue |
|---|---|
| MacroGenics | 157.08M |
| Codexis | 78.09M |
| Coherus Oncology | 46.88M |
| Adagene | 7.67M |
| Entrada Therapeutics | 5.74M |
| AC Immune | 4.62M |
| SAB Biotherapeutics | 114.70K |
CLLS News
- 8 hours ago - Monthly information on share capital and company voting rights - GlobeNewsWire
- 6 days ago - Cellectis initiated with an Overweight at Barclays - TheFly
- 13 days ago - Cellectis Slides: Corporate presentation - Filings
- 14 days ago - Cellectis' Annual Shareholders General Meeting to be Held on June 25, 2026 - GlobeNewsWire
- 22 days ago - Cellectis (CLLS) Announces Clinical Trial Presentations at EHA Congress - GuruFocus
- 22 days ago - Cellectis to present clinical data on lasme-cel, eti-cel at EHA Congress - TheFly
- 22 days ago - Cellectis to Present Clinical Data on Lasme-cel and Eti-cel at EHA 2026 Annual Congress - GlobeNewsWire
- 23 days ago - Cellectis (CLLS) Reports Strong Cash Position for Future Operations - GuruFocus